A new study published in the Journal of Evidence-Based Medicine by Daoyuan Lai and colleagues, a team of researchers from the University of Hong Kong, has made significant strides in understanding the safety of COVID-19 mRNA vaccines, particularly in relation to myocarditis risk after vaccination. The study may also represent a watershed moment in the methodology used to assess causality using VAERS data.
The study, which focuses on the rare but concerning risk of myocarditis following the administration of COVID-19 mRNA vaccines, introduces a novel approach to analyzing vaccine safety data that could transform how we monitor vaccine adverse events.
The study analyzed data from the US Vaccine Adverse Event Reporting System (VAERS), a resource that has been used to monitor post-vaccination adverse events. Recognizing the limitations of data in VAERS, including potential underreporting and the absence of a control group, the team employed a modified version of the Self-Controlled Case Series (SCCS) method. This innovative approach allowed for more accurate detection and quantification of myocarditis risk following the second and third doses of mRNA COVID-19 vaccines.
Hellbound and Down 